China’s drug test backlog creates private equity niche

TPG is expanding a Taiwanese clinical trial firm to help cut China's long queue for new drugs. The deal is another step in the private equity firm’s plan to create a pan-Asian CRO.

China’s drug test backlog creates private equity niche

US private equity firm TPG has bought a majority stake in Taiwanese clinical trials provider, OPC Holding, which it plans to expand into China, the world’s second largest pharmaceutical market.

The acquisition, announced on Monday, is another step in TPG’s plan to create a pan-Asian clinical drug trials firm, also known in the industry as a contract research organisation CRO.

The other leg of the nascent regional CRO is...

To continue reading, please login or register for free

Click for more on: cfda | tpg | private | equity | opc | health | china | regulation | taiwan

Print Edition

FinanceAsia Print Edition

CONFERENCES